Shionogi Signs Development & Commercialization Agreement with Akili for its AKL-T01 and AKL-T02 for ADHD & ASD
Shots:
- Akili to receive $20M upfront- $105M as development & commercialization milestones- making the total the deal value $125M & royalties on sales of the products. Shionogi to get exclusive development & commercialization rights for Akili’s digital medicine- AKL-T01 and AKL-T02 in Japan and Taiwan
- Acc. to an agreement- Shionogi will be responsible for regulatory filings in Japan & Taiwan. Akili has an exclusive global right to develop & commercialize its digital medicines excluding Japan & Taiwan
- Akili’s AKL-T01 and AKL-T02 are a digital treatment for attention-deficit/hyperactivity disorder (ADHD) & Autism Spectrum Disorder (ASD) respectively in children
Ref: Akili | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com